Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14211627 | 1.00 | SLC6A3 (0.61) | SLC6A3SLC6A2SLC6A4DHFRTDP1 | |
| SCHEMBL14233517 | 1.00 | SLC6A3 (0.61) | SLC6A3SLC6A2SLC6A4DHFRTDP1 | |
| SCHEMBL5570406 | 0.87 | SLC6A3 (0.49) | SLC6A3SLC6A2SLC6A4TDP1ALDH1A1 | |
| SCHEMBL14438434 | 0.87 | SLC6A3 (0.49) | SLC6A3SLC6A2SLC6A4TDP1ALDH1A1 | |
| SCHEMBL10391386 | 0.86 | SLC6A3 (0.49) | SLC6A3TDP1ALDH1A1LMNATSHR | |
| SCHEMBL8637525 | 0.86 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4DHFRTDP1 | |
| SCHEMBL10918428 | 0.84 | SLC6A3 (0.50) | SLC6A3TDP1ALDH1A1LMNATSHR | |
| SCHEMBL54014 | 0.83 | SLC6A3 (0.46) | SLC6A3TDP1ALDH1A1LMNATSHR | |
| SCHEMBL8637626 | 0.81 | TSHR (0.60) | SLC6A3TDP1ALDH1A1LMNATSHR | |
| SCHEMBL23349257 | 0.80 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4DHFRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20240382600-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-4395828-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023031801-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | disclosed |
| EP-4121421-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Novartis AG (CH) | 2023-01-25 | — | — | EP | disclosed |
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2021-09-30 | — | — | US | disclosed |
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2021-09-30 | — | — | US | disclosed |
| WO-2021186324-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021186324-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2021-09-23 | — | — | WO | disclosed |
| EP-2387574-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110253463-A1 | MODULAR HYBRID ELECTRIC VEHICLE SYSTEM | SMITH MARK ERIC | 2011-10-20 | — | — | US | disclosed |
| US-20100184799-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| WO-2010083136-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2010-07-22 | — | — | WO | disclosed |
| EP-1538148-B1 | CHIRAL SENSOR | JAPAN SCIENCE & TECH AGENCY (JP) | 2007-01-10 | — | — | EP | disclosed |
| EP-0323864-A2 | Lipophilic oxadiazoles | MERCK SHARP & DOHME LTD. (GB) | 1989-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382600-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | YAP1, JMJD7, TOR1AIP1 | SLC6A3 3165/4885SLC6A2 2652/4885SLC6A4 3589/4885 |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | YAP1, TEAD3, TEAD2 | SLC6A3 3806/4885SLC6A2 3628/4885SLC6A4 4459/4885 |
| US-20100184799-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | GPR119, SSTR3, SSTR2 | SLC6A3 283/4885SLC6A2 404/4885SLC6A4 308/4885 |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | SLC6A3 3806/4885SLC6A2 3628/4885SLC6A4 4459/4885 |
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | SLC6A3 3875/4885SLC6A2 3704/4885SLC6A4 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.